Other equities research analysts also recently issued research reports about the stock. JPMorgan Chase & Co. set a €87.70 ($108.27) price objective on shares of Gerresheimer and gave the company a buy rating in a research report on Thursday, January 4th. Commerzbank set a €77.00 ($95.06) price objective on shares of Gerresheimer and gave the company a buy rating in a research report on Monday, February 5th. Credit Suisse Group set a €75.00 ($92.59) price objective on shares of Gerresheimer and gave the company a buy rating in a research report on Wednesday, February 21st. DZ Bank reissued a buy rating on shares of Gerresheimer in a research report on Monday, February 26th. Finally, Deutsche Bank set a €66.00 ($81.48) price objective on shares of Gerresheimer and gave the company a neutral rating in a research report on Monday, January 22nd. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and four have given a buy rating to the stock. The company currently has a consensus rating of Hold and an average price target of €69.85 ($86.24).
Shares of Gerresheimer (GXI) opened at €67.00 ($82.72) on Friday. Gerresheimer has a 1 year low of €59.97 ($74.04) and a 1 year high of €78.25 ($96.60). The stock has a market cap of $2,090.00 and a price-to-earnings ratio of 20.87.
Gerresheimer AG manufactures and sells specialty glass and plastic products primarily for the pharma and healthcare industry worldwide. It operates through two divisions, Plastics & Devices, and Primary Packaging Glass. The Plastics & Devices division offers drug delivery systems, including inhalers, pen systems, and injection systems; sterile and non-sterile prefillable syringe systems for the pharmaceutical and biotech industries; and disposables for various analysis systems that are used in laboratories and medical practices, quick tests for patients in medical practices or hospitals, skin-prick aids and lancets for diabetics, disposables and components for dialysis machines, and catheters and surgical devices.
Receive News & Ratings for Gerresheimer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gerresheimer and related companies with MarketBeat.com's FREE daily email newsletter.